Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis

Biol Blood Marrow Transplant. 2014 Nov;20(11):1869-70. doi: 10.1016/j.bbmt.2014.07.023. Epub 2014 Jul 25.

Authors

Betty Ky Hamilton¹, Matt Kalaycio²

Affiliations

¹ Blood and Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio. Electronic address: hamiltb2@ccf.org.
² Blood and Marrow Transplant Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

PMID: 25065905
DOI: 10.1016/j.bbmt.2014.07.023

No abstract available

Publication types

Letter
Comment

MeSH terms

Female
Graft vs Host Disease / prevention & control*
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Immunosuppressive Agents / therapeutic use*
Male
Mycophenolic Acid / analogs & derivatives*
Tacrolimus / therapeutic use*
Transplantation Conditioning / adverse effects*

Substances

Immunosuppressive Agents
Mycophenolic Acid
Tacrolimus